The FDA has issued a Class II recall for Teva Pharmaceuticals' Metoprolol Succinate Extended-Release Tablets (50 mg, 100 and 1,000 tablet bottles) because the product failed dissolution specifications. This recall impacts distribution nationwide and is currently ongoing, identified by recall number D-0355-2026.

Drug manufacturers and distributors must ensure any affected product is removed from the market and returned according to recall procedures. Compliance officers should verify that their inventory does not contain the affected lots and implement procedures to prevent future occurrences of dissolution specification failures. While no specific compliance deadline is stated, the ongoing nature of the recall implies immediate action is required to cease distribution and manage recalled inventory.